Lataa...
Addition of H19 ‘Loss of Methylation Testing’ for Beckwith-Wiedemann Syndrome (BWS) Increases the Diagnostic Yield
Beckwith-Wiedemann syndrome (BWS) is a clinical diagnosis; however, molecular confirmation via abnormal methylation of DMR2(LIT1) and/or DMR1(H19) has clinical utility due to epigenotype-tumor association. Despite the strong link between H19 hypermethylation and tumor risk, several diagnostic labora...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Investigative Pathology
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2928421/ https://ncbi.nlm.nih.gov/pubmed/20616360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2353/jmoldx.2010.100005 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|